Short answer: In an exploratory randomized trial in Headache, psilocybin did not clearly beat an active placebo for migraine prevention. One 10 mg dose looked numerically better than two 10 mg doses a week apart, but the differences were not statistically significant.
Eighteen adults were randomized to diphenhydramine twice, psilocybin once plus diphenhydramine once, or psilocybin twice. In the first 2 weeks after the second session, weekly migraine-day reduction was about −0.7, −2.0, and −1.7 respectively (p = 0.102). The 2-week 50 percent responder rate was 17 percent for placebo vs 80 percent for the psilocybin arms (p = 0.087). Across 8 weeks, all groups improved by roughly 50 percent.
Blinding appeared imperfect even with an active placebo, and 10 mg may be a suboptimal dose. No serious unexpected adverse events were reported. Larger, well controlled studies are needed to test superiority and to compare one vs two doses with adequate dosing.
I cannot independently verify the 2025 publication details. Bottom line: a promising signal, not proof.